

**DOCKET NO.: ISIS0185-101 (ISPH-0569)****PATENT**

Patents recited above were commonly owned at the time the invention in the present application was made. Applicants enclose herewith three Statements by Jodi L. Connolly, Ph.D., a patent agent at Isis Pharmaceuticals, Inc., asserting the common ownership at the time of the invention. Accordingly, Applicants respectfully request that the rejections under 35 U.S.C. §103(a) be withdrawn.


**II. Obviousness-Type Double Patenting**

Claims 23 and 28 are provisionally rejected under the doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 2-5 of co-pending application Serial No. 10/454,293. Although Applicants reserve the right to present remarks rebutting the substance of the present provisional rejection, Applicants respectfully request that this provisional rejection be withdrawn in the present application because, upon withdrawal of the obviousness rejections recited above, the provisional rejection is the only remaining rejection.

**III. Conclusion**

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. An early notice of the same is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at (215) 665-6914 if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,



Paul K. Legaard, Ph.D.  
Registration No. 38,534

Date: 20 April 2005  
Enclosures

COZEN O'CONNOR  
1900 Market Street  
Philadelphia, PA 19103-3508  
Telephone: (215) 665-6914  
Facsimile: (215) 701-2141